News & Updates

A new tool for identifying potentially inappropriate prescribing (PIP) in people with type 2 diabetes (T2D) has been validated in the outpatient setting, according to an Ethiopian study.

In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).

Potent and selective inhibition of IL-17A by izokibep produced a rapid improvement in disease activity across multiple psoriatic arthritis (PsA) domains, according to preliminary data from a phase IIb/III trial.

Upadacitinib remains effective through 5 years in patients with rheumatoid arthritis (RA) who have inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with no new safety signals, as shown by the results of the phase III long-term extension (LTE) of SELECT-NEXT.

Findings from the phase IV INHALE-3 trial support inhaled insulin for the management of type 1 diabetes (T1D) in adults, underlining its role as an alternative insulin solution to enhance diabetes management.